Advances in management of thalassemia

Indian Pediatrics

Volumn 41, Issue 10, 2004, Pages 989-992

  Agarwal, M B ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIRETROVIRUS AGENT; BETA GLOBIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEPATITIS B VACCINE; HORMONE; INOTROPIC AGENT; IRON; IRON CHELATING AGENT; LAMIVUDINE; PAMIDRONIC ACID; PEGINTERFERON; RIBAVIRIN;

ARTHRITIS; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CHELATION THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; DEVELOPING COUNTRY; EDITORIAL; ENDOCRINE DISEASE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEALTH CARE COST; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PHLEBOTOMY; PUBLIC HEALTH; SIDE EFFECT; THALASSEMIA; VACCINATION; ZINC DEFICIENCY;

BONE DISEASES, METABOLIC; CHILD; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; OSTEOPOROSIS; THALASSEMIA;

EID: 7044246004     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Cunningham MJ, Macklin EA, Newfeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004; 104:34-39.
2. De SV. Growth and puberty and its management in thalassemia. Horm Res 2002; 58 Suppl 1: 72-79.
3. Hui L, Leung MP, Ha SY, Chau AKT, Cheung YF. Early detection of left ventricular dysfunction in patients with beta thal major by dobutamine stress echocardiography. Heart 2003; 89: 669-670.
4. Westwood M, Anderson LJ, Pennell DJ. Treatment of cardiac iron overload in thalassemia major (Ed). Hematologica 2003; 88: 481-482.
5. Jensen PD. Evaluation of iron overload. Br J Haematol 2004; 124: 697-711.
6. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta thalassemia major: Application of SQUID biomagnetic liver susceptometry. Br J Hematol 2003; 121: 938-948.
7. Anderson LJ, Davis HB, Prescott E, Charrier CC, Bunce NH, Firmin DN, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179.
8. Jensen PD, Jansen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with desferrioxamine indication of close relation between myocardial iron content and chelation iron pool. Blood 2003; 101: 4632-4639.
9. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566-1569.
10. Agarwal MB. ICL 670: A new oral chelator: A major breakthrough in treatment of thalassemia. Ind J Hematol B1 Trans 2003, 31: 26-28.
11. Cheung YF, Chan GCF, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 2002; 106: 2561-2566.
12. Voskardou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, et al. Pamidronate is an effective treatment for osteoporosis in patients with β-thalassemia. Br J Hematol 2003; 123: 730-737.
13. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thal syndromes. Br J Haematol 2004; 124: 114-117
14. Erer B, Lucarelli G. Bone marrow transplantation in thalassemia. Turk J Hematol 1999; 16: 147-159.